Acquired Aplastic Anemia
7
1
2
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
29%
2 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Unrelated And Partially Matched Related Donor PSCT w/ T Cell Receptor (TCR) αβ Depletion for Patients With BMF
Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA
Cord Blood Transplantation in Severe Aplastic Anemia
Randomised Study Comparing Different Dosages of Rabbit ATG in Patients With SAA
Haploidentical Stem Cell Transplantation for Children With Acquired Severe Aplastic Anemia